Article Text

Download PDFPDF
Effect of dapagliflozin in patients with heart failure
  1. Teck K Khong1,
  2. Joshua Au Yeung2
  1. 1 Clinical Pharmacology, St George's University of London, London, UK
  2. 2 Clinical Pharmacology, St Thomas' Hospital, London, UK
  1. Correspondence to Dr Teck K Khong, Clinical Pharmacology, St George's University of London, London, UK; tkhong{at}sgul.ac.uk

Abstract

Commentary on: McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019;381:1995–2008.

Commentary by: Dr Joshua Au Yeunga, Clinical Pharmacology, St Thomas’ Hospital, London, UK and Dr Teck Khong, Clinical Pharmacology, St George’s, University of London, UK.

Series Editor: Dr Teck Khong, DTB Associate Editor, Clinical Pharmacology, St George’s, University of London, UK.

  • drug-related side effects and adverse reactions
  • healthcare quality
  • access
  • and evaluation

Statistics from Altmetric.com

Footnotes

  • Competing interests None declared. Refer to the online supplementary files to view the ICMJE form(s).

  • Provenance and peer review Commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.